Term ends Jun 6, 2028 · Medium confidence
20-year base term ends Jun 6, 2028
Why Medium: A parent in the chain could not be resolved.
Held by Aptalis Pharma Canada ULC
Filed Jun 1, 2009 as application 12/476,185 · Granted Jul 10, 2012
Base term plus 322 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2008
2028
Clock starts
Jun 6, 2008
Jun 6, 2008
Term ends
Jun 6, 2028
Jun 6, 2028
Granted
Jul 10, 2012
Jul 10, 2012
base term
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
322
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 7,541,384.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
28
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 322 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 6, 2008, when application 12/135,103, the earliest non-provisional in its chain, was filed (this one was filed Jun 1, 2009); a parent in its chain could not be resolved (the next row) | Jun 6, 2028 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +322 days, USPTO patent term adjustment record | Apr 24, 2029 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,541,384) | capped to Jun 6, 2028 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 6, 2028 | Medium confidence |
This family
| US 8,604,222 | Lapsed on the fee record Dec 2025 | Dec 2025 |
| US 8,246,950 | In force Feb 2028 | Feb 2028 |
| US 8,221,747 | In force Feb 2028 | Feb 2028 |
| US 8,293,229 | In force Mar 2031 | Mar 2031 |
| US 7,541,384 | In force Jun 2028 | Jun 2028 |
| US 10,087,493 | In force Mar 2029 | Mar 2029 |
| US 8,217,083 | this patent Jun 2028 | Jun 2028 |
| US 8,784,884 | In force Aug 2031 | Aug 2031 |
8 of 28 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 8, 2009 Reel 22925, frame 887 | Gauthier, Carl; Dumoulin, Yves; Powell, David | Axcan Pharma Inc. | Assignment of Assignor's Interest |
| Dec 13, 2011 Reel 27373, frame 622 | Axcan Pharma Inc. | Axcan Pharma Canada Inc. | Change of Name |
| Dec 16, 2011 Reel 27401, frame 722 | Axcan Pharma Inc. | Aptalis Pharma Canada Inc. | Change of Name |
| Oct 31, 2013 Reel 31531, frame 488 | Aptalis Pharma Canada Inc.; Aptalis Pharma US, Inc.; Aptalis Pharmatech, Inc. | Bank of America, N.A., as Administrative Agent | Patent Security Agreement |
| Jan 31, 2014 Reel 32149, frame 111 | Bank of America, N.A., as Administrative Agent | Aptalis Pharma US, Inc.; Aptalis Pharmatech, Inc.; Aptalis Pharma Canada Inc. | Termination and Release |
| Jan 31, 2014 reel/frame not recorded | Bank of America, N.A., as Administrative Agent | Aptalis Pharma US, Inc. | Termination and Release |
| Jan 31, 2014 reel/frame not recorded | Bank of America, N.A., as Administrative Agent | Aptalis Pharmatech, Inc. | Termination and Release |
| Jan 31, 2014 reel/frame not recorded | Bank of America, N.A., as Administrative Agent | Aptalis Pharma Canada Inc. | Termination and Release |
| Mar 18, 2016 Reel 38037, frame 424 | Aptalis Pharma Canada Inc. | Aptalis Pharma Canada ULC | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Jun 2028
Term ends Jun 6, 2028. No further fees fall due before then
Note
The 322 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 7,541,384.
Citations
4
later US patents cite this one
That is below the median of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.